Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Specific PARP1-PROTAC degrader shows anticancer activity in preclinical models

Dec. 11, 2020

How stress disrupts tumor cell sleep

Dec. 11, 2020

SABCS2020: Verzenio continues to show benefit, but time may topple monarchE

Dec. 10, 2020

Activity seen with ZEN-003694 plus talazoparib in metastatic triple-negative breast cancer

Dec. 10, 2020

Dana-Farber Cancer Institute patents focal adhesion kinase inhibitors

Dec. 10, 2020

New aryl hydrocarbon receptor antagonists disclosed by Antidote IP Holdings

Dec. 10, 2020

FDA clears IND for first-in-human study of KB-0742 for MYC-amplified tumors

Dec. 9, 2020

Teligene identifies new protein kinase inhibitors

Dec. 9, 2020

ACSS2 inhibitors discovered at Metabomed

Dec. 9, 2020

ION-251 enters first-in-human trial for relapsed or refractory multiple myeloma

Dec. 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Combination locked out in ATTR-CM? ‘Dead,’ expert says
BioWorld
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...